Best single time point correlations with AUC for cyclosporine and tacrolimus in hiv-infected kidney and liver transplant recipients

Transplantation

Volumn 97, Issue 6, 2014, Pages 702-707

  Frassetto, Lynda A ^a   Tan Tam, Clara C ^a   Barin, Burc ^b   Browne, Matt ^a   Wolfe, Alan R ^a   Stock, Peter G ^a   Roland, Michelle ^a   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EMMES   (United States)

Author keywords

Antiretrovirals; Drug interactions; HIV; Immunosuppressants; Pharmacokinetics

Indexed keywords

CYCLOSPORIN; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; TACROLIMUS;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY TRANSPLANTATION; LIQUID CHROMATOGRAPHY; LIVER TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OBSERVATIONAL STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; CYCLOSPORINE; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; GRAFT REJECTION; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TACROLIMUS; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897024102     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000441097.30094.31     Document Type: Article

References (21)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853.
2. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-Associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30(Suppl 1): S5.
3. Frassetto LA, Tan-Tam C, Stock PG. Renal transplantation in patients with HIV. Nat Rev Nephrol 2009; 5: 582.
4. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7: 2816.
5. Transplant Study for People with HIV. Available at: Http:// www.hivtransplant.com/. Accessed July 31, 2013.
6. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363: 2004.
7. Alstrup K, Kangas I, Laursen AL, et al. Renal transplantation in an HIV-infected patient: Pharmacokinetic aspects. Scand J Urol Nephrol 2011; 45: 216.
8. Bickel M, Anadol E, Vogel M, et al. Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir. J Antimicrob Chemother 2010;65: 999.
9. Barau C, Blouin P, Creput C, et al. Effect of coadministered HIVprotease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. Fundam Clin Pharmacol 2009; 23: 423
10. Teicher E, Vincent I, Bonhomme-Faivre L, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 2007; 46: 941.
11. Knight SR, Morris PJ. The clinical benefits of cyclosporine C2-level monitoring: A systematic review. Transplantation 2007; 83: 1525.
12. Kim SJ, Prasad GV, Huang M, et al. A comparison of the effects of C2-cyclosporine and C0-Tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients. Transplantation 2006; 82: 924.
13. Frassetto L, Baluom M, Jacobsen W, et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005; 80: 13.
14. International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148.
15. Cantarovich M, Barkun JS, Tchervenkov JI, et al. Comparison of Neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 1998; 66: 1621.
16. Kumar MS, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIVpositive patients. Kidney Int 2005; 67: 1622.
17. van Maarseveen EM, van Zuilen AD, Mudrikova T. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2011; 364: 683.
18. Floren LC, Bekersky I, Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62: 41.
19. Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9: 1946.
20. Christians U, Jacobsen W, Serkova N, et al. Automated, fast and sensitive quantification of drugs in blood by liquid chromatographymass spectrometry with on-line extraction: Immunosuppressants. J Chromatogr B 2000; 748: 41.
21. PDR Network, Physician's Desk Reference. 65rd Ed. Montvale, NJ: Physician's Desk Reference Inc; 2011; 439: 2560.